Not enough data
Neil Osterweil's focus is on medical research, with a significant emphasis on citing data. He seems to be particularly interested in developments related to cancer treatment, liver disease, respiratory health, and pulmonary hypertension. His interest in scientific themes suggests he may appreciate pitches that offer in-depth analysis of new studies or clinical trials within the healthcare and pharmaceutical sectors.
Given his strong reliance on data, he would likely respond well to pitches offering access to experts who can provide insights into recent studies or breakthroughs within these fields. Additionally, sources with first-hand knowledge of the latest findings or those involved in cutting-edge research could be valuable for Neil's coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Neil Osterweil
The novel antibody-drug conjugate sacituzumab tirumotecan continues to show significant survival benefit for patients with previously treated advanced EGFR-mutated non-small cell lung cancer compared with docetaxel, investigators from the OptiTROP-Lung03 trial reported.
By: Neil Osterweil
The updated EV-302 trial results show that enfortumab vedotin plus pembrolizumab significantly improves overall survival in metastatic urothelial cancer compared to chemotherapy.
By: Neil Osterweil
Explore the efficacy of a novel ADC combo in phase 2 bladder cancer data, highlighting promising results and potential treatment advancements.
By: Neil Osterweil
Explore how daraxonrasib is transforming pancreatic cancer treatment by doubling survival rates, as showcased at ASCO 2026.
By: Neil Osterweil
The PROTEUS trial shows that perioperative androgen receptor pathway inhibitor therapy improves metastasis-free survival in high-risk localized prostate cancer.
By: Neil Osterweil
Zele combined with pembrolizumab shows promise for advanced bladder cancer, with a favorable safety profile compared to enfortumab vedotin and pembrolizumab.
Afami-cel, the first FDA-approved TCR therapy for synovial sarcoma, shows durable response rates and strong overall survival in advanced cases.
By: Neil Osterweil
Explore the top research on diffuse large B-cell lymphoma presented at ASCO 2026, including advances in treatment and patient outcomes.
March 12, 2013 | Family Practice News Author and Disclosure Information EXPERT ANALYSIS FROM THE ADA ADVANCED POSTGRADUATE COURSE
March 6, 2013 | Family Practice News Author and Disclosure Information EXPERT ANALYSIS FROM THE ADA ADVANCED POSTGRADUATE COURSE
